Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on March 9, 2016. The report announces the financial results for the fourth quarter and the full fiscal year ended December 31, 2015. The company is incorporated in Delaware and headquartered in Boston, Massachusetts.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the results for Q4 and FY 2015 have been announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the correct registrant name is Zafgen, Inc., as the input metadata incorrectly listed Larimar Therapeutics, Inc.
- Review Exhibit 99.1 (the March 9, 2016 press release) to obtain actual financial figures for Q4 and FY 2015.
- Confirm the company's current operational status, as Zafgen has since undergone significant corporate changes (including bankruptcy and acquisition) not reflected in this 2016 filing.